

Adverse effects of  
trimethoprim-sulfamethoxazole for the  
prophylaxis of Pneumocystis pneumonia in  
dermatology.

著者	KOKUBU Hiraku, KATO Takeshi, NISHIKAWA Junko, TANAKA Toshihiro, FUJIMOTO Noriki
journal or publication title	The Journal of dermatology
year	2021-01-25
URL	<a href="http://hdl.handle.net/10422/00012905">http://hdl.handle.net/10422/00012905</a>

doi: 10.1111/1346-8138.15724(<https://doi.org/10.1111/1346-8138.15724>)



### Adverse effects of trimethoprim-sulfamethoxazole for the prophylaxis of *Pneumocystis pneumonia* in dermatology

Journal:	<i>The Journal of Dermatology</i>
Manuscript ID	JDE-2020-1391.R1
Wiley - Manuscript type:	Concise Communication
Date Submitted by the Author:	n/a
Complete List of Authors:	Kokubu, Hiraku ; Shiga University of Medical Science, Department of Dermatology Kato, Takeshi; Shiga University of Medical Science, Department of Dermatology Nishikawa, Junko ; Shiga University of Medical Science, Department of Dermatology Tanaka, Toshihiro; Shiga Univ Medical Science, Dermatology Fujimoto, Noriki; Shiga University of Medical Science, Department of Dermatology
Keywords:	Adverse effects, Antibiotic Premedication, Asians, Dermatology, Trimethoprim-Sulfamethoxazole
Abstract:	<p>Objectives: Trimethoprim-sulfamethoxazole (TMP/SMX) combination is used for the prophylaxis of <i>Pneumocystis pneumonia</i> (PCP). Although TMP/SMX is frequently used in dermatology for cases treated with corticosteroids and/or immunosuppressants, it is often difficult to continue the administration of TMP/SMX due to adverse events. There are only a few reported studies on the prophylaxis of PCP in dermatology. This is the first review focused on adverse events of TMP/SMX among patients with dermatological diseases compared to previous reports.</p> <p>Methods: In this study, we retrospectively investigated 132 cases treated with TMP/SMX and examined the adverse events.</p> <p>Results: Adverse events occurred in 32 cases (24.2%), and the incidence in this study was higher than in previous reports. Thrombocytopenia occurred in 17 cases (12.5%), which was the most frequent adverse event. The possible causes of adverse events were the standard dose of TMP/SMX might be excess for most Japanese, in addition to the long administration period, and the concomitant use of corticosteroids and/or immunosuppressants in almost all cases.</p> <p>Conclusion: We must consider the risks of PCP and adverse events of TMP/SMX in each case. It is desirable to examine possible administration methods that can be continued by adjusting the dose and interval of TMP/SMX.</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7 1 Adverse effects of trimethoprim-sulfamethoxazole for the prophylaxis of

8  
9 2 *Pneumocystis* pneumonia in dermatology

10  
11  
12 3 Running title: Adverse effects of TMP/SMX

13  
14  
15  
16 4

17  
18 5 Hiraku Kokubu, MD; Takeshi Kato, MD, PhD; Junko Nishikawa, MD;

19  
20  
21 6 Toshihiro Tanaka, MD, PhD; and Noriki Fujimoto, MD, PhD

22  
23  
24 7 Department of Dermatology, Shiga University of Medical Science,

25  
26  
27 8 Setatsukinowa, Otsu, Shiga 520-2192, Japan; Phone: 81-77-548-2233.

28  
29  
30 9 FAX: 81-77-548-2154

31  
32  
33 10 Corresponding author: Hiraku Kokubu, MD; E-mail: kokubu@belle.shiga-

34  
35  
36 11 med.ac.jp; Phone: 81-77-548-2233; FAX: 81-77-548-2154

37  
38  
39 12 Word count: 1500 words, 1 figure, 2 tables, and 14 references

40  
41  
42 13

43  
44  
45 14

46  
47  
48 15

49  
50  
51 16

52  
53  
54 17

55  
56  
57 18

1  
2  
3  
4  
5  
6 **1 Abstract**

7  
8  
9 **2 Objectives:** Trimethoprim-sulfamethoxazole (TMP/SMX) combination is  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
used for the prophylaxis of *Pneumocystis pneumonia* (PCP). Although  
TMP/SMX is frequently used in dermatology for cases treated with  
corticosteroids and/or immunosuppressants, it is often difficult to continue  
the administration of TMP/SMX due to adverse events. There are only a  
few reported studies on the prophylaxis of PCP in dermatology. This is the  
first review focused on adverse events of TMP/SMX among patients with  
dermatological diseases compared to previous reports.

**10 Methods:** In this study, we retrospectively investigated 132 cases treated  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
with TMP/SMX and examined the adverse events.

**12 Results:** Adverse events occurred in 32 cases (24.2%), and the incidence in  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
this study was higher than in previous reports. Thrombocytopenia occurred  
in 17 cases (12.5%), which was the most frequent adverse event. The  
possible causes of adverse events were the standard dose of TMP/SMX  
might be excess for most Japanese, in addition to the long administration  
period, and the concomitant use of corticosteroids and/or  
immunosuppressants in almost all cases.

1 **Conclusion:** We must consider the risks of PCP and adverse events of  
2 TMP/SMX in each case. It is desirable to examine possible administration  
3 methods that can be continued by adjusting the dose and interval of  
4 TMP/SMX.

5  
6 Key words: Adverse effects, Antibiotic Premedication, Asians, Dermatology,  
7 Trimethoprim-Sulfamethoxazole

## 8 9 **Introduction**

10 *Pneumocystis pneumonia* (PCP) is a serious disease caused by  
11 *Pneumocystis jirovecii*, and the survival rate is 52.9% for dermatology  
12 patients.<sup>1</sup> It develops in the background of underlying diseases, such as  
13 AIDS, malignant tumors, and collagen diseases treated with high-dose  
14 corticosteroids and/or immunosuppressants.

15 Trimethoprim-sulfamethoxazole (TMP/SMX) combination has been  
16 reported to have a preventive effect against PCP.<sup>2</sup> Dermatologists  
17 frequently administer TMP/SMX to patients with pemphigus, pemphigoid,  
18 dermatomyositis, and systemic lupus erythematosus. Because we treat

1 these patients with corticosteroids and/or immunosuppressants for a long  
2 period of time, adverse events often occur, so we often reduce the dose of  
3 TMP/SMX due to adverse events.<sup>3</sup> We have managed to use TMP/SMX  
4 without causing adverse events.<sup>4</sup> A non-blind randomized controlled trial is  
5 now in progress.<sup>5</sup> However, there are only a few reported studies on the  
6 prophylaxis of PCP in dermatology.<sup>6</sup> In this study, we investigated the  
7 frequency of adverse events in patients with dermatological diseases who  
8 received TMP/SMX for the prophylaxis of PCP.

## 9 10 **Methods**

11 **Patients:** We enrolled patients with dermatological diseases who were  
12 hospitalized at the Department of Dermatology of Shiga University of  
13 Medical Science and who received TMP/SMX for prophylaxis of PCP  
14 from July 2010 to October 2017. We administered TMP/SMX to patients  
15 who were treated with high-dose corticosteroids (>20 mg/day for ≥1  
16 month, until reduced approximately <10 mg/day).

17 **Study design:** A retrospective review of 132 patients who were  
18 administered TMP/SMX was conducted. Each tablet of TMP/SMX

1 included 80 mg TMP and 400 mg SMX. We administered TMP/SMX at  
2 the dosage of 1 tablet daily, 0.5 tablet daily, 1 tablet every other day, 2  
3 tablets twice weekly, or 2 tablets daily depending on the case **without**  
4 **specific rules**. Data included age, sex, primary diseases, dosage of  
5 TMP/SMX, presence or absence of adverse events, and their contents.  
6 **Follow-up period was from July 2010 to October 2017**. We regarded  
7 adverse events in cases for whom **other causes for the events were**  
8 **excluded**, TMP/SMX was needed to be reduced or discontinued, **and then**  
9 **confirmed an improvement of adverse events**. **Instead of rechallenge, we**  
10 **administered atovaquone or pentamidine isethionate by inhalation**. This  
11 study was approved by the Research Ethics Committee of Shiga University  
12 of Medical Science (reference number R2017-221).  
13 **Statistical analysis:** We collected the case data and compared the incidence  
14 of adverse events for each primary disease, dosage of TMP/SMX, presence  
15 or absence of concomitant drugs, and patients' ages. Statistical analysis  
16 was performed using  $\chi^2$  test or Student's t-test.

## 17 18 **Results**



1  
2  
3  
4  
5  
6  
7 1 ***Patient characteristics:*** A total of 132 patients were enrolled (60 males and  
8  
9 2 72 females aged 17 to 49 years; Table 1). The primary diseases were  
10  
11 3 bullous pemphigoid (28 patients), dermatomyositis (22 patients),  
12  
13 4 pemphigus vulgaris (9 patients), pyoderma gangrenosum (7 patients), adult  
14  
15 5 Still's disease (6 patients), malignant lymphoma (5 patients), systemic  
16  
17 6 lupus erythematosus (5 patients), pemphigus foliaceus (5 patients), and  
18  
19 7 others (45 patients). Adverse events occurred below 13 years old (0 case),  
20  
21 8 at 13 to 65 years old (20 of 72 cases; 27.8%), and above 65 years old (12 of  
22  
23 9 60 cases; 20.0%). There was no statistical significance in the incidence of  
24  
25 10 adverse events between their age, sex, and primary diseases.  
26  
27  
28  
29  
30  
31  
32  
33  
34

35  
36 11 ***Incidence of adverse events:*** Although no patients developed PCP, adverse  
37  
38 12 events occurred in 32 cases (24.2%). Adverse events included  
39  
40 13 erythrocytopenia (2.2%), leukocytopenia (2.2%), thrombocytopenia  
41  
42 14 (12.5%), elevated liver enzyme (5.9%), renal dysfunction (1.5%), and drug  
43  
44 15 eruption (4.5%). **Out of 6 drug eruptions, 5 cases were maculopapular**  
45  
46 16 **eruption (day10, 11, 12, 21, 30), and 1 case was toxic epidermal necrolysis**  
47  
48 17 **(day 11).** Adverse events occurred at the dosage of 1 tablet daily (29 of 115  
49  
50  
51  
52  
53  
54  
55 18 cases), 0.5 tablet daily (1 of 7 cases), 2 tablets daily (1 of 2 cases), 2 tablets  
56  
57  
58  
59  
60

1 twice weekly (0 of 6 cases), and 1 tablet every other day (1 of 2 cases). We  
2 summarized the incidence of adverse events in this study and from previous  
3 reports (Table 2).<sup>7-10</sup> The incidence of hematologic problem and elevated  
4 liver enzyme in this study (daily administration; n = 124) was significantly  
5 higher than that of El-Sadr, et al. (daily administration; n = 1312). There  
6 are no relationship and significant difference between the accumulated  
7 doses of TMX/SMX and onset of adverse events.

8 ***Time of onset of adverse events:*** The time of onset of adverse events was  
9 within 1 week (18.8%), from 1 week to 1 month (26.3%), and more than 1  
10 month (25.0%). We created a box-and-whisker plot that shows the day of  
11 onset of each adverse event (Figure 1). The onset of adverse events was on  
12 days 2 to 66; renal dysfunction most often occurred at about 1 week,  
13 elevated liver enzyme and drug eruption at about 2 weeks, and cytopenia at  
14 about 2 to 3 weeks. There were no significant differences in the day of  
15 onset of each adverse event.

## 16 17 **Discussion**

1 In our study, there were significant differences in the incidence of  
2 hematologic problem and elevated liver enzyme.<sup>7-10</sup> Of course, we could  
3 not simply compare these results due to the difference of primary diseases,  
4 observation period, and definition of adverse events. We **discuss** three  
5 **perspectives** for these results. (1) **Prophylaxis of TMX/SMX needs longer-**  
6 **term than administration as a treatment of an infection**, which may increase  
7 the chances of adverse events. Although cytopenia was relatively rare in a  
8 **treatment of infection**, it was frequently seen in our study: erythrocytopenia  
9 (2.6%), leukocytopenia (2.2%), and thrombocytopenia (12.5%). It was  
10 considered that TMP/SMX caused cytopenia by impairing folic acid  
11 metabolism and that long-term administration might cause metabolic  
12 abnormalities and folate deficiency depending on the period, resulting in  
13 increased incidence of cytopenia.<sup>11</sup> **However, there were no significant**  
14 **difference between the accumulated doses of TMX/SMX and onset of**  
15 **adverse events. It is not clear whether an administration period is related to**  
16 **the incidence of the adverse events.**

17 (2) We treated our patients with combined medication of corticosteroids  
18 and/or immunosuppressants for primary diseases in almost all cases.

1 Immunocompromised patients sometimes needed other various drugs, for  
2 example, ganciclovir for cytomegalovirus infection, which might have  
3 interacted with TMP/SMX. (3) In Table 2, the results of El-Sadr WM et al.  
4 showed that the dosage of TMP/SMX apparently involved the incidence of  
5 adverse events. One study proved that there was a significant dose-  
6 dependent increasing trend in adverse events of TMP/SMX.<sup>12</sup> For Japanese,  
7 it might be better to reduce the dose or frequency of TMP/SMX, although  
8 we could not prove that the incidence of adverse events was related the race  
9 or BMI of patients. There are no reports that discussed whether or not we  
10 can reduce the dosage of TMP/SMX in safety.

11 It was reported that the incidence of adverse events with thrice-weekly  
12 administration of TMP/SMX was significantly lower than that with daily  
13 administration, and there was no significant difference in the PCP  
14 incidence rate between daily and thrice-weekly administration.<sup>9</sup> The results  
15 of our study were similar to that of previous reports, although the number  
16 of cases was limited.

17 Although we should be cautious of adverse events, some reports showed  
18 that the odds ratio of PCP development due to discontinuation of

1  
2  
3  
4  
5  
6 1 TMP/SMX is 4.77 times **in HIV-infected patients**.<sup>9</sup> Guidelines in the  
7  
8  
9 2 United States suggested that we better eventually restart TMP/SMX for  
10  
11  
12 3 cases in which it was discontinued due to a mild adverse event.  
13  
14  
15 4 Approximately 70% of patients were able to continue TMP/SMX by  
16  
17  
18 5 reducing the dose/interval or desensitization therapy.<sup>13</sup>  
19  
20

21 6 Although the mechanism of adverse effects of TMP/SMX and the risk  
22  
23  
24 7 factors have been almost clear,<sup>11</sup> we need to be cautious of the occurrence  
25  
26  
27 8 of adverse events of TMP/SMX for each case. One study reported that  
28  
29  
30 9 routine prophylaxis is unnecessary for patients with autoimmune blistering  
31  
32  
33 10 diseases, who do not usually need strong immunosuppression.<sup>14</sup> We should  
34  
35  
36 11 consider the risks of PCP and adverse events of TMP/SMX in each case, as  
37  
38  
39 12 necessary, and examine possible administration methods that can be  
40  
41  
42 13 continued by adjusting the dose and interval of TMP/SMX for patients with  
43  
44  
45 14 dermatological diseases.  
46  
47

48  
49 15

## 51 16 **ACKNOWLEDGMENTS**

52  
53  
54 17 Financial support: none  
55  
56

57  
58 18  
59  
60

## 1 CONFLICTS OF INTEREST

2 The authors have no conflicts of interest declared.

## 4 REFERENCES

- 5 1 Gonzalez Santiago TM, Wetter DA, Kalaaji AN, Limper AH, Lehman  
6 JS. Pneumocystis jiroveci pneumonia in patients treated with systemic  
7 immunosuppressive agents for dermatologic conditions: a systematic  
8 review with recommendations for prophylaxis. *Int J Dermatol* 2016;  
9 **55**: 823-830.
- 10 2 Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK et al. A  
11 controlled trial of aerosolized pentamidine or trimethoprim-  
12 sulfamethoxazole as primary prophylaxis against *Pneumocystis*  
13 *carinii* pneumonia in patients with human immunodeficiency virus  
14 infection. The Dutch AIDS Treatment Group. *N Engl J Med* 1992;  
15 **327**: 1836-1841.
- 16 3 Prasad GVR, Beckley J, Mathur M et al. Safety and efficacy of  
17 prophylaxis for *Pneumocystis jirovecii* pneumonia involving  
18 trimethoprim-sulfamethoxazole dose reduction in kidney

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

transplantation. *BMC Infect Dis* 2019; **19**: 311.

4 Leoung GS, Stanford JF, Giordano MF et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for *Pneumocystis Carinii* pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. *J Infect Dis* 2001; **184**: 992-997.

5 Abe Y, Fujibayashi K, Nishizaki Y et al. Conventional-dose Versus Half-dose Sulfamethoxazole-trimethoprim for the Prophylaxis of *Pneumocystis Pneumonia* in Patients with Systemic Rheumatic Disease: A Non-blind, Randomized Controlled Trial. *Acta Med Okayama* 2019; **73**: 85-89.

6 Lehman JS, Kalaaji AN. Role of primary prophylaxis for *pneumocystis pneumonia* in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions. *J Am Acad Dermatol* 2010; **63**: 815-823.

7 Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for *pneumocystis*

- 1 pneumonia in patients with rheumatic diseases exposed to prolonged  
2 high-dose glucocorticoids. *Ann Rheum Dis* 2018; **77**: 644-649.
- 3 8 Torre-Cisneros J, De la Mata M, Pozo JC et al. Randomized trial of  
4 weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim-  
5 sulfamethoxazole for the prophylaxis of *Pneumocystis carinii*  
6 pneumonia after liver transplantation. *Clin Infect Dis* 1999; **29**: 771-  
7 774.
- 8 9 El-Sadr WM, Luskin-Hawk R, Yurik TM et al. A randomized trial of  
9 daily and thrice-weekly trimethoprim-sulfamethoxazole for the  
10 prevention of *Pneumocystis carinii* pneumonia in human  
11 immunodeficiency virus-infected persons. Terry Bein Community  
12 Programs for Clinical Research on AIDS (CPCRA). *Clin Infect Dis*  
13 1999; **29**: 775-783.
- 14 10 Podzamczar D, Salazar A, Jimenez J et al. Intermittent trimethoprim-  
15 sulfamethoxazole compared with dapsone-pyrimethamine for the  
16 simultaneous primary prophylaxis of *Pneumocystis pneumonia* and  
17 toxoplasmosis in patients infected with HIV. *Ann Intern Med* 1995;  
18 **122**: 755-761.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1 11 Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-  
2 sulfamethoxazole. *Cmaj* 2011; **183**: 1851-1858.
- 3 12 Ohmura S-i, Naniwa T, Tamechika S-y et al. Effectiveness and safety  
4 of lower dose sulfamethoxazole/trimethoprim therapy for  
5 *Pneumocystis jirovecii* pneumonia in patients with systemic rheumatic  
6 diseases: A retrospective multicenter study. *Journal of Infection and*  
7 *Chemotherapy* 2019; **25**: 253-261.
- 8 13 Masur H, Brooks JT, Benson CA et al. Prevention and treatment of  
9 opportunistic infections in HIV-infected adults and adolescents:  
10 Updated Guidelines from the Centers for Disease Control and  
11 Prevention, National Institutes of Health, and HIV Medicine  
12 Association of the Infectious Diseases Society of America. *Clin Infect*  
13 *Dis* 2014; **58**: 1308-1311.
- 14 14 Amber KT, Lamberts A, Solimani F et al. Determining the Incidence  
15 of Pneumocystis Pneumonia in Patients With Autoimmune Blistering  
16 Diseases Not Receiving Routine Prophylaxis. *JAMA Dermatol* 2017;  
17 **153**: 1137-1141.
- 18

1  
2  
3  
4  
5  
6 **1 FIGURE LEGEND**  
7

8  
9 2 Figure 1. Box-and-whisker plot shows the day of onset of each adverse  
10  
11  
12 3 event  
13  
14

15 4

16  
17  
18 **5 TABLES**  
19

20  
21 6 Table 1. Patient characteristics  
22

23  
24 7 Table 2. The incidence of adverse events comparison with previous reports  
25

26  
27 8 \* **Daily administered** cases of this study versus daily administered cases of  
28

29  
30 9 El-Sadr WM, et al.  
31

32  
33 10 **HIV: human immunodeficiency virus; LT: liver transplantation; ND: Not**  
34

35  
36 11 **described; RD: Rheumatic diseases**  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Box-and-whisker plot shows the day of onset of each adverse event  
380x260mm (72 x 72 DPI)

Table 1 Patient characteristics

	Our cases (n= 132)	Adverse events (n= 32)	P value
Age (average± standard deviation)	60.6± 17.8	59.0± 18.0	0.54
Sex (man/woman)	60/72	10/22	1
Primary disease			
Bullous pemphigoid (%)	28	7 (25%)	0.97
Dermatomyositis (%)	22	6 (27.7%)	0.9
Pemphigus vulgaris (%)	9	3 (33.3%)	0.83
Pyoderma gangrenosum (%)	7	1 (14.3%)	0.82
Adult still's disease (%)	6	2 (33.3%)	0.86
Malignant lymphoma (%)	5	1 (20%)	0.94
Systemic lupus erythematosus (%)	5	2 (40%)	0.78
Pemphigus foliaceus (%)	5	1 (20%)	0.94
Others (%)	45	9 (20%)	0.78

Table 2 The incidence of adverse events comparison with previous reports

	This study						#7	#8	#9	#10		
Disease	Dermatological diseases						RD	After LT	Patients infected with HIV			
Dosing interval	Total	Daily			Twice weekly	Every other day	Daily or thrice-weekly	Daily		Twice weekly	Thrice weekly	P value*
Daily dose of Trimethoprim (mg)		80	40	160	320	80	ND	80	160	320		
Daily dose of Sulfamethoxazole (mg)		400	200	800	1600	400	ND	400	800	1600		
Number of cases	132	115	7	2	6	2	262	60	1312	1313	104	
Adverse events (%)	32 (24.2)	29 (25.2)	1 (14.3)	1 (50)	0	1 (50)	34 (13.0)	11 (18.3)	255 (19.4)	126 (9.6)	ND	0.15
Hematologic (%)	20 (15.2)	18 (15.7)	1 (14.3)	0	0	1 (50)	6 (2.3)	6 (10.0)	72 (5.5)	17 (1.3)	ND	<0.0001
Erythrocytopenia (%)	3 (2.6)	3 (2.6)	0	0	0	0	2 (0.8)	ND	ND	ND	21 (20.2)	ND
Leukocytopenia (%)	3 (2.2)	3 (2.6)	0	0	0	0	1 (0.4)	3 (5.0)	ND	ND	39 (37.5)	ND
Thrombocytopenia (%)	17 (12.5)	15 (13.0)	1 (14.3)	0	0	1 (50)	3 (1.2)	3 (5.0)	ND	ND	11 (10.6)	ND
Elevated liver enzyme (%)	8 (5.9)	8 (7.0)	0	0	0	0	6 (2.3)	3 (5.0)	11 (0.8)	2 (0.2)	18 (17.3)	<0.00001
Renal dysfunction (%)	2 (1.5)	2 (1.7)	0	0	0	0	5 (1.9)	ND	7 (0.5)	3 (0.2)	ND	0.16
Drug eruption (%)	6 (4.5)	5 (4.3)	0	1 (50)	0	0	7 (2.7)	ND	ND	ND	9 (8.7)	ND
Intestinal problem (%)	0	0	0	0	0	0	2 (0.8)	2 (3.3)	24 (1.8)	10 (0.8)	17 (16.3)	0.16
Hypersensitivity (%)	ND	ND	ND	ND	ND	ND	ND	ND	130 (9.9)	86 (6.5)	ND	ND
Others (%)	0	0	0	0	0	0	9 (3.4%)	ND	6 (0.5)	4 (0.3)	14 (13.5)	0.48

\* Daily administered cases of this study versus daily administered cases of El-Sadr WM, et al.

HIV: human immunodeficiency virus; LT: liver transplantation;

ND: Not described; RD: Rheumatic diseases